文献速递新发突发、热带与寄生虫病

COVID-19大流行对非洲疟疾干预覆盖、发病和死亡的间接影响:地理空间建模分析

Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis.
PubMed 文献 · Lancet Infect Dis · 2020-09-21

该研究利用时空贝叶斯地统计模型,评估非洲疟疾流行国家在COVID-19相关干预中断下2020年疟疾发病和死亡的可能变化。若同时减少虫媒蚊帐和药物覆盖,负担进一步加重。

核心结论

  • 在悲观情景下,COVID-19相关疟疾控制中断可能使2020年非洲疟疾死亡几乎翻倍,并可能在后续年份导致更大增幅。

研究设计与样本

  • 使用已建立的时空贝叶斯地统计模型,结合更新的寄生虫率调查、杀虫剂处理蚊帐覆盖和有效治疗率数据库,生成非洲疟疾流行国家临床病例发病和死亡的地理空间估计。
  • 建立无COVID-19相关中断的2020年非洲疟疾负担基线估计,并针对抗疟药有效治疗和蚊帐分发(常规渠道和 масс 运动)不同程度减少的九种假设情景重复分析。

临床怎么用

  • 在COVID-19应对中应维持疟疾核心干预(有效抗疟药治疗和蚊帐分发),避免覆盖下降导致发病和死亡增加。
  • 决策者需将避免疟疾控制倒退作为与COVID-19响应并行的综合优先事项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Substantial progress has been made in reducing the burden of malaria in Africa since 2000, but those gains could be jeopardised if the COVID-19 pandemic affects the availability of key malaria control interventions. The aim of this study was to evaluate plausible effects on malaria incidence and mortality under different levels of disruption to malaria control. METHODS: Using an established set of spatiotemporal Bayesian geostatistical models, we generated geospatial estimates across malaria-endemic African countries of the clinical case incidence and mortality of malaria, incorporating an updated database of parasite rate surveys, insecticide-treated net (ITN) coverage, and effective treatment rates. We established a baseline estimate for the anticipated malaria burden in Africa in the absence of COVID-19-related disruptions, and repeated the analysis for nine hypothetical scenarios in which effective treatment with an antimalarial drug and distribution of ITNs (both through routine channels and mass campaigns) were reduced to varying extents. FINDINGS: We estimated 215·2 (95% uncertainty interval 143·7-311·6) million cases and 386·4 (307·8-497·8) thousand deaths across malaria-endemic African countries in 2020 in our baseline scenario of undisrupted intervention coverage. With greater reductions in access to effective antimalarial drug treatment, our model predicted increasing numbers of cases and deaths: 224·1 (148·7-326·8) million cases and 487·9 (385·3-634·6) thousand deaths with a 25% reduction in antimalarial drug coverage; 233·1 (153·7-342·5) million cases and 597·4 (468·0-784·4) thousand deaths with a 50% reduction; and 242·3 (158·7-358·8) million cases and 715·2 (556·4-947·9) thousand deaths with a 75% reduction. Halting planned 2020 ITN mass distribution campaigns and reducing routine ITN distributions by 25%-75% also increased malaria burden to a total of 230·5 (151·6-343·3) million cases and 411·7 (322·8-545·5) thousand deaths with a 25% reduction; 232·8 (152·3-345·9) million cases and 415·5 (324·3-549·4) thousand deaths with a 50% reduction; and 234·0 (152·9-348·4) million cases and 417·6 (325·5-553·1) thousand deaths with a 75% reduction. When ITN coverage and antimalarial drug coverage were synchronously reduced, malaria burden increased to 240·5 (156·5-358·2) million cases and 520·9 (404·1-691·9) thousand deaths with a 25% reduction; 251·0 (162·2-377·0) million cases and 640·2 (492·0-856·7) thousand deaths with a 50% reduction; and 261·6 (167·7-396·8) million cases and 768·6 (586·1-1038·7) thousand deaths with a 75% reduction. INTERPRETATION: Under pessimistic scenarios, COVID-19-related disruption to malaria control in Africa could almost double malaria mortality in 2020, and potentially lead to even greater increases in subsequent years. To avoid a reversal of two decades of progress against malaria, averting this public health disaster must remain an integrated priority alongside the response to COVID-19. FUNDING: Bill and Melinda Gates Foundation; Channel 7 Telethon Trust, Western Australia.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Weiss DJ, Bertozzi-Villa A, Rumisha SF, et al. Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis. Lancet Infect Dis. 2020. PMID: 32971006. doi:10.1016/S1473-3099(20)30700-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。